The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Original Article

Osteoporosis Treatment Following Hip Fracture: How Rates Vary by Service

Authors: Patricia C. Gregory, MD, Diana Lam, BS, Paul Howell, MD

Abstract

Objectives: Osteoporosis is a prevalent condition among older people. It is often undiagnosed until patients suffer fragility fractures. Previous studies have shown low rates of initiating osteoporosis treatment during the acute hip fracture hospitalization. It is not clear if this varies by the treating service. We compared the rates of instituting osteoporosis treatment during the acute hospitalization for fragility hip fractures.


Methods: Rates of initiating treatment among previously untreated patients were compared between the orthopedic, medicine, and rehabilitation services using retrospective cross-sectional chart review at an academic medical center. Between January 2005 and August 2008, 191 patients admitted with a fragility hip fracture survived to be discharged from the hospital.


Results: There were 67 (35%) patients who were started on some form of osteoporosis treatment during their acute hospital stay. Factors statistically associated with starting treatment included having a discharge diagnosis of osteoporosis (P < 0.0001) and treating service (P < 0.0001). Orthopedics was the least likely of the 3 treating services to initiate treatment, while medicine was the most likely.


Conclusions: Overall rates of osteoporosis treatment initiation were low at 35% of the 191 patients' records surveyed. Efforts to increase adherence during the acute hospital stay should be explored. A promising intervention includes instituting an osteoporosis consultative service to improve the likelihood of starting osteoporosis treatment post fragility fracture.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

 
2. NIH Consensus Development Program. Osteoporosis Prevention, Diagnosis, and Therapy. Bethesda, MD, National Institutes of Health, 2000. Available at: http://consensus.nih.gov/2000/2000Osteoporosis11html.htm. Accessed January 6, 2010.
 
3. World Health Organization. WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level. Geneva, World Health Organization, 2007. [See comment in Intro: World Health Organization. Assessment of osteoporotic fracture risk and its role in screening for postmenopausal osteoporosis. WHO Technical report series no. 843. Geneva: World Health Organization 1994.]
 
4. Qaseem A, Snow V, Shekelle P, et al; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008;149:404–415.
 
5. Lüthje P, Nurmi-Lüthje I, Kaukonen JP, et al. Undertreatment of osteoporosis following hip fracture in the elderly. Arch Gerontol Geriatr 2009;49:153–157.
 
6. Gallagher TC, Geling O, Comite F. Missed opportunities for prevention of osteoporotic fracture. Arch Int Med 2002;162:450–456.
 
7. Andrade SE, Majumdar SR, Chan KA, et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 2003;163:2052–2057.
 
8. Byszewski AM, Cranney A, Man-Son-Hing M, et al. Evaluation of in-hospital management of fracture risk in older patients: a chart review study of tertiary prevention. Arch Gerontol Geriatr 2006;42:319–328.
 
9. Cree MW, Juby AG, Carriere KC. Mortality and morbidity associated with osteoporosis drug treatment following hip fracture. Osteoporosis Int 2003;14:722–727.
 
10. Juby AG, De Geus-Wenceslau CM. Evaluation of osteoporosis treatment in seniors after hip fracture. Osteoporos Int 2002;13:205–210.
 
11. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333–340.
 
12. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535–1541.
 
13. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799–1809.
 
14. Dirschl DR, Piedrahita L, Henderson RC. Bone mineral density 6 years after a hip fracture: a prospective, longitudinal study. Bone 2000;26:95–98.
 
15. Magaziner J, Hawkes W, Hebel JR, et al. Recovery from hip fracture in eight areas of function. J Gerontol A Biol Sci Med Sci 2000;55:M498–M507.
 
16. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294–1301.
 
17. Morris CD, Einhorn TA. Bisphosphonates in orthopaedic surgery. J Bone Joint Surg Am 2005;87:1609–1618.
 
18. Kiebzak GM, Moore NL, Margolis S, et al. Vitamin D status of patients admitted to a hospital rehabilitation unit: relationship to function and progress. Am J Phys Med Rehabil 2007;86:435–445.
 
19. Islam S, Liu Q, Chines A, Helzner E. Trend in incidence of osteoporosis-related fractures among 40- to 69-year-old women: analysis of a large insurance claims database, 2000–2005. Menopause 2009;16:77–83.
 
20. Adolphson P, Abbaszadegan H, Bodén H, et al. Clodronate increases mineralization of callus after Colles' fracture: a randomized, double-blind, placebo-controlled, prospective trial in 32 patients. Acta Orthop Scand 2000;71:195–200.
 
21. Streeten EA, Mohamed A, Gandhi A, et al. The inpatient consultation approach to osteoporosis treatment in patients with a fracture. Is automatic consultation needed? J Bone Joint Surg Am 2006;88:1968–1974.
 
22. Harrington JT, Barash HL, Day S, et al. Redesigning the care of fragility fracture patients to improve osteoporosis management: a health care improvement project. Arthritis Rheum 2005;53:198–204.
 
23. Kaufman JD, Bolander ME, Bunta AD, et al. Barriers and solutions to osteoporosis care in patients with a hip fracture. J Bone Joint Surg Am 2003;85:1837–1843.
 
24. Feldstein AC, Nichols G, Orwoll E, et al. The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int 2005;16:953–962.